Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 19, 2026SHILAP Revista de lepidopterologíaOpen Access

P01 | Circulating Tumor Cells Improve Risk Stratification According to the Second Revision of the International Staging System and the Ims-Imwg Consensus Genomic Staging in NDMM Patients. An Analysis From the European CTC Consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

MDM. D'AgostinoAzienda Ospedaliera Citta' della Salute e della Scienza di TorinoEME. Martín-SánchezClinica Universidad de NavarraDŽD. ŽihalaUniversity of Ostrava

Discussion

Loading...

Member takes

Implication

Analysis shows circulating tumor cells improve risk stratification in NDMM patients, suggesting enhanced prognostic capabilities.

Key Points

  • The study evaluates the clinical significance of circulating tumor cells in conjunction with R2-ISS and IMS-IMWG CGS in newly diagnosed multiple myeloma patients.
  • Analyzed data from the European CTC Consortium, including 1673 NDMM patients for R2-ISS and 190 patients for CGS.
  • CTC enumeration was performed using flow cytometry prior to treatment.
  • Statistical models were developed to assess the prognostic value of CTCs alongside R2-ISS and CGS.
  • CTC levels significantly predicted progression-free survival (PFS) with independent HR values in both R2-ISS and CGS cohorts.
  • PFS was notably longer for patients with low CTC levels compared to high CTC levels across all R2-ISS stages.
  • The integration of CTCs into prognostic models improved risk stratification for both R2-ISS and CGS, as shown by higher C-indices.

Cite This Study

D'Agostino et al. (2026) studied this question.

synapsesocial.com/papers/69e4702d010ef96374d8d670https://doi.org/10.3324/haematol.2026.s2.14064
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.2025 · 2 citations
  2. 2B04 | BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM2026
  3. 3P26 | CORRELATION OF THE CIRCULATING TUMOR CELLS AND R2-ISS SCORE IN NEWLY DIAGNOSED MYELOMA PATIENTS: RWE EXPERIENCE2026
  4. 4Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma2024 · 12 citations
  5. 5R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study2024 · 4 citations